Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 270 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatic Failure Clear all

Conditions: Hepatic Insufficiency
Interventions: Evacetrapib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions: Not listed
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: One meal; Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy, Hepatic Insufficiency
Interventions: Canagliflozin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: End Stage Liver Disease
Interventions: Advance Care Planning Video Decision Support Tool, Verbal Narrative; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 70 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Chicago, Illinois • Ithaca, New York • New York, New York + 2 more

Conditions: Hepatic Encephalopathy
Interventions: AXA1665, Placebo; Drug
Lead sponsor: Axcella Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 21
States / cities: San Francisco, California • DeBary, Florida • Gainesville, Florida + 15 more

Conditions: Acute-On-Chronic Liver Failure
Interventions: SMT + PE-A 5%, Standard Medical Treatment; Biological · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Cirrhosis
Interventions: BreathID (Methacetin breath test); Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Detroit, Michigan • Charleston, South Carolina • Richmond, Virginia

Conditions: HIV Infections, Hepatic Insufficiency
Interventions: nevirapine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Bakersfield, California • San Francisco, California • Albany, New York + 1 more

Conditions: Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions: Medically-tailored meals (MTM), Protein supplements, Nutrition education handout; Other · Dietary Supplement · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin, placebo; Drug
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatic Insufficiency
Interventions: Mavorixafor; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Montclair, California • Rialto, California • Orlando, Florida + 1 more

Conditions: Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome, Acute Tubule Necrosis, Prerenal Failure
Interventions: MAP-Target Algorithm; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Liver Failure
Interventions: Anti-Thymocyte Globulin, ATG (Rabbit), Total lymphoid irradiation; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Stanford, California

Conditions: End Stage Liver DIsease, Liver Failure
Interventions: hypothermic oxygenated perfusion therapy of a donor liver under standard of care conditions; Device
Lead sponsor: Bridge to Life Ltd.; Industry
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Hepatitis, Chronic Hepatitis
Interventions: ELAD plus standard of care treatment, Standard of care treatment; Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 19 Years to 69 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: La Jolla, California • San Francisco, California • Chicago, Illinois + 3 more

Conditions: Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions: Rifaximin (drug); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions: Not listed
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Hepatic Insufficiency, Liver Diseases, Pharmacokinetics, Drug Metabolism
Interventions: Sevabertinib; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Hepatic Impairment
Interventions: Ferriprox®; Drug
Lead sponsor: ApoPharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: End Stage Cardiac Failure, Pulmonary Failure, End Stage Liver Disease, Morbid Obesity, Recalcitrant Epilepsy Requiring Surgery, Healthy Subjects
Interventions: To surgery patients, Tocopherol capsules., Tocotrienol to healthy subjects., To surgery patients, Tocotrienol capsules.; Dietary Supplement
Lead sponsor: Chandan K Sen; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hepatic Insufficiency
Interventions: AXA1665, Placebo; Dietary Supplement
Lead sponsor: Axcella Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Montclair, California • Tustin, California • Miami Lakes, Florida + 8 more

Conditions: Virus Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Multi-Center Study of Iron Overload: Pilot Study

Effect of Brief Dietary Intervention on Ammonia Levels

A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function

A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver Disease

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

Rifaximin in Minimal Hepatic Encephalopathy

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation

VitaSmart HOPE System: Bridge to HOPE Registry

Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol

Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

Collection of Liver Tissue for Virologic Studies